Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 6/20 | 0.33 |
| ▸ | TDO2 | P48775 | 5/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567434 | 0.82 | ALDH1A1 (0.50) | TDP1TP53SMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL30793060 | 0.82 | ALDH1A1 (0.50) | TDP1TP53SMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL16550138 | 0.73 | POLB (0.34) | MAPTTDP1NPC1RAB9AACHE | |
| SCHEMBL13086248 | 0.73 | ALDH1A1 (0.52) | HSD17B10LMNAMAPTESR2TDP1 | |
| SCHEMBL1040241 | 0.73 | ACHE (0.35) | LMNACYP2C9CYP2C19ACHEIDO1 | |
| SCHEMBL1043230 | 0.73 | IDO1 (0.44) | LMNAMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18234142 | 0.71 | MPL (0.41) | ACHEPDE3BPDE3A | |
| SCHEMBL21183074 | 0.70 | ACHE (0.32) | TDP1TP53SMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL22416498 | 0.70 | CYP3A4 (0.52) | HSD17B10MAPTESR2TDP1NPC1 | |
| SCHEMBL31590604 | 0.70 | ALDH1A1 (0.55) | HSD17B10LMNAMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
| EP-0684951-B1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMA INC (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5523442-A | TREATING ALZHEIMER'S, DEMENTIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0684951-A1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS. | MERRELL DOW PHARMA (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019356-A1 | SILYLATED ACETYLCHOLINESTERASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0611769-A1 | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | HSD17B10 1926/4885LMNA 2551/4885MAPT 3462/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | HSD17B10 1926/4885LMNA 2551/4885MAPT 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.